Jun 2026 (Q2 FY26) — Aug 12, 2026
IceCure Medical Ltd Q2 FY26 — Commercial Momentum and Clinical Reinforcement
Read the full callIceCure Medical (ICCM) earnings
- Jun 2026 (Q2 FY26)
- Dec 2025
IceCure Medical earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Price
$1.04 0.00% · $0
Performance −95.9% 1Y
1Y: $25.34 on 14 Oct 2025 → $1.04. High $25.81 (15 Oct 2025), low $1.04 (14 Oct 2026).
- Previous close
- $1.04
- 52-week range
- $1.04 – $25.81
- One year
- −95.97%
Overview
- Symbol
- ICCM
- Sector
- Health Care
- Industry
- Surgical & Medical Instruments & Apparatus
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
IceCure Medical earnings calls (ICCM)
Financials
What the filings say
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Reserves | — | -49 | -58 | -75 | -90 | -105 | -120 |
| Total liabilities | — | 5 | 5 | 5 | 4 | 6 | 5 |
| Fixed assets | — | 0 | 1 | 1 | 2 | 1 | 1 |
| Investments | — | — | — | — | 1 | — | — |
| Total assets | — | 10 | 32 | 30 | 16 | 13 | 14 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -2 | -4 | -13 | -14 | -13 | -13 | -15 |
| Cash from investing | -0 | -5 | 4 | -1 | -1 | 0 | -0 |
| Cash from financing | 3 | 6 | 31 | 14 | 0 | 9 | 16 |
| Net cash flow | 1 | -3 | 22 | -2 | — | — | — |
| Capital expenditure | -0 | -0 | -1 | -1 | -0 | -0 | -0 |
| Free cash flow | -2 | -4 | -13 | -15 | -13 | -13 | -15 |
Insider filings
5 filings, all on Aug 14, 2026.
Open market
decisions to buy or sellNobody bought or sold ICCM on the open market in this window. The filings below are 5 awards.
Compensation
not trading decisions- 5
- Award — granted as compensation
Latest filings (5)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 14, 2026 | Peleg Meir Chief Financial Officer | Award | 181,483 | $0 |
| Aug 14, 2026 | Dotan Merav Nir VP, Human Resources | Award | 73,890 | $0 |
| Aug 14, 2026 | Levav Shay Chief Operating Officer | Award | 141,483 | $0 |
| Aug 14, 2026 | Tel-Tzure Tlalit Bussi VP, BD & Global Marketing | Award | 101,483 | $0 |
| Aug 14, 2026 | Good Shad VP, Sales for North America | Award | 131,483 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for IceCure Medical Ltd.
Free account. Everything above stays public.
Write why you follow IceCure Medical Ltd. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading